{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T02:39:43Z","timestamp":1648867183807},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1992,3,1]],"date-time":"1992-03-01T00:00:00Z","timestamp":699408000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[1992,3]]},"DOI":"10.1007\/bf02529689","type":"journal-article","created":{"date-parts":[[2006,11,10]],"date-time":"2006-11-10T05:52:34Z","timestamp":1163137954000},"page":"13-17","source":"Crossref","is-referenced-by-count":1,"title":["Risiko-Nutzen-Betrachtungen bei der Therapie mit nicht-opioiden Analgetika"],"prefix":"10.1007","volume":"6","author":[{"given":"K.","family":"Menges","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02529689_CR1","first-page":"20","volume-title":"Arzneiverordnungs-Report","year":"1990","unstructured":"Schwabe U, Paffrath D (Hrgb.) (1990) Arzneiverordnungs-Report. Bd. 6 Gustav Fischer Verlag, Stuttgart S 20"},{"key":"BF02529689_CR2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000168002","volume":"9","author":"W Pommer","year":"1989","unstructured":"Pommer W, Bronder E, Greiser E, Helmert U, Jesdinsky HJ, Klimpel A, Borner K, Molzahn M (1989) Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 9: 403","journal-title":"Am J Nephrol"},{"key":"BF02529689_CR3","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM198905113201903","volume":"320","author":"DP Sandler","year":"1989","unstructured":"Sandler DP, Smith JC, Weinberg CR, Buckalew VM Jr, Dennis VW, Blythe WB, Burgess WP (1989) Analgesic use and chronic renal disease. New Engl J Med 320: 1238","journal-title":"New Engl J Med"},{"key":"BF02529689_CR4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2125.1990.tb03841.x","volume":"30","author":"M Morlans","year":"1990","unstructured":"Morlans M, Laporte JR, Vidal X, Cabeza D, Stolley PD (1990) End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmac 30: 717","journal-title":"Br J Clin Pharmac"},{"key":"BF02529689_CR5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000185116","volume":"50","author":"M Segasothy","year":"1988","unstructured":"Segasothy M, Suleiman AB, Puvaneswary M, Rohana A: Paracetamol (1988) A cause of analgesic nephropathy and end-stage renal disease. Nephron 50: 50","journal-title":"Nephron"},{"key":"BF02529689_CR6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1056\/NEJM199101173240304","volume":"324","author":"UC Dubach","year":"1991","unstructured":"Dubach UC, Rosner B, St\u00fcrmer T (1991) An epidemiologic study of abuse of analgesic drugs. Effects of Phenacetin and Salicylate on mortality and cardiovascular morbidity (1968 to 1987). New Engl J Med 324: 155","journal-title":"New Engl J Med"},{"key":"BF02529689_CR7","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/archinte.1983.00350090053009","volume":"143","author":"TG Murray","year":"1983","unstructured":"Murray TG, Stolley PD, Anthony JC, Shinnar R, Hepler-Smith E, Jeffreys JL (1983) Epidemiological study of regular analgesic use and end-stage renal disease. Arch Int Med 143: 1687","journal-title":"Arch Int Med"},{"key":"BF02529689_CR8","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.1986.03380130077032","volume":"256","author":"The International Agranulocytosis and Aplastic Anaemia Study (IAAAS)","year":"1986","unstructured":"The International Agranulocytosis and Aplastic Anaemia Study (IAAAS). Risks of agranulocytosis and aplastic Anaemia. A first report of their relation to drug use with special reference to analgesics. J Am Med Ass (1986) 256: 1749","journal-title":"J Am Med Ass"},{"key":"BF02529689_CR9","unstructured":"Abwehr von Arzneimittelrisiken (Stufe II), Metamizol-haltige Kombinationsarzneimitel. Bescheid des Bundesgesundheitsamtes vom 13.2.1990"},{"key":"BF02529689_CR10","first-page":"1994","volume":"84","author":"H Immich","year":"1987","unstructured":"Immich H (1987) Inzidenzen unerheblich (Leserbrief). Dt. \u00c4rztebl. 84: 1994","journal-title":"Dt. \u00c4rztebl."},{"key":"BF02529689_CR11","first-page":"194","volume-title":"Pharmakotherapie-Klinische Pharmakologie","author":"E Hackenthal","year":"1986","unstructured":"Hackenthal E (1986) Analgetika. in: F\u00fclgraff G, Palm D (Hrsgb.). Pharmakotherapie-Klinische Pharmakologie. 6. Aufl. Gustav Fischer Verlag, Stuttgart S 194","edition":"6. Aufl."},{"key":"BF02529689_CR12","first-page":"155","volume-title":"100 Jahre Pyrazolone. Eine Bestandsaufnahme","author":"R Hoign\u00e9","year":"1985","unstructured":"Hoign\u00e9 R, Zoppi M, Sollberger J, Hess T, Fritschy D (1985) Arterielle Hypotonie, wahrscheinlich nicht allergischer Pathogenese, als Nebenwirkung der Injektion von Metamizol. in: Brune K, Lanz R (Hrsgb.): 100 Jahre Pyrazolone. Eine Bestandsaufnahme. Urban und Schwarzenberg, M\u00fcnchen, Wien Baltimore, S 155"},{"key":"BF02529689_CR13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archinte.1991.00400070083009","volume":"151","author":"RA Hoppmann","year":"1991","unstructured":"Hoppmann RA, Peden JG, Ober SK (1991) Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, Psychosis, and cognitive dysfunction. Arch Intern Med 151: 1309","journal-title":"Arch Intern Med"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02529689.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02529689\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02529689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T20:55:02Z","timestamp":1558299302000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02529689"}},"subtitle":["Wie h\u00e4ufig sind Analgetika-Nephropathie und Agranulozytose?"],"short-title":[],"issued":{"date-parts":[[1992,3]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1992,3]]}},"alternative-id":["BF02529689"],"URL":"https:\/\/doi.org\/10.1007\/bf02529689","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,3]]}}}